Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acusphere, Inc.
Acusphere, Inc. Reports Q2 2008 Financial Results and Business Highlights
August 29th, 2008
Acusphere, Inc. (NASDAQ: ACUS) reported financial results for the second quarter ended June 30, 2008 and commented on its financial results and business highlights. Major Accomplishments -- Submitted New Drug Application (NDA) to the U.S. Food & Drug Administration for its lead product candidate, Imagify(TM) (Perflubutane Polymer Microspheres) for Injectable Suspension. -- Announced FDA acceptance of NDA, with expected target action date under the Prescription Drug User Fee Act (PDUFA) of February 28, 2009. -- Amended agreement with Nycomed to receive up to $750,000 in payments associated with qualification of...
Source: Health Business Week (2008-08-29)
|
